New facility will manufacture active pharmaceutical ingredients for medicines like Foundayo (orforglipron), strengthening domestic supply chain Site will employ more than 600 people in high-wage jobs $12. 5 million in support to build talent pipeline, workforce training center with San Jacinto College HOUSTON, Sept. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) broke ground today in Houston, Texas, one of ten U.S. manufacturing sites - and fifth location to produce domestic active pharmaceutical ingredients (API) - announced since 2020.

As part of the company's $50 billion push to reshore medicine production to meet growing demand at home and export American-made medicines to people around the world, the $6. 5 billion Houston site will manufacture Foundayo (orforglipron), Lilly's first synthetic oral GLP-1 medicine, along with other small-molecule medicines and advanced therapeutics.

Foundayo is a GLP-1 receptor agonist approved in the U.S. for weight management in adults with obesity, or adults with overweight and a weight-related condition.